Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2026)

Oramed Pharmaceuticals filings provide 4 years of Non Operating Income readings, the most recent being $15.2 million for Q4 2025.

  • Quarterly Non Operating Income rose 486.26% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.4 million through Dec 2025, up 5755.53% year-over-year, with the annual reading at $89.5 million for FY2025, 331411.11% up from the prior year.
  • Non Operating Income hit $15.2 million in Q4 2025 for Oramed Pharmaceuticals, down from $61.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $61.5 million in Q3 2025 and bottomed at -$15.4 million in Q3 2024.
  • Average Non Operating Income over 4 years is $6.3 million, with a median of $1.3 million recorded in 2022.
  • The largest annual shift saw Non Operating Income plummeted 3644.83% in 2024 before it skyrocketed 498.64% in 2025.
  • Oramed Pharmaceuticals' Non Operating Income stood at $1.0 million in 2022, then plummeted by 547.88% to -$4.5 million in 2023, then rose by 12.62% to -$3.9 million in 2024, then surged by 486.26% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Non Operating Income are $15.2 million (Q4 2025), $61.5 million (Q3 2025), and $15.4 million (Q2 2025).